MX2020011665A - Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica. - Google Patents

Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica.

Info

Publication number
MX2020011665A
MX2020011665A MX2020011665A MX2020011665A MX2020011665A MX 2020011665 A MX2020011665 A MX 2020011665A MX 2020011665 A MX2020011665 A MX 2020011665A MX 2020011665 A MX2020011665 A MX 2020011665A MX 2020011665 A MX2020011665 A MX 2020011665A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
addition salt
crystal form
receptor agonist
crystalline form
Prior art date
Application number
MX2020011665A
Other languages
English (en)
Spanish (es)
Inventor
Wei Zheng
Wubin Pan
Jiawang Guo
Original Assignee
Suzhou Connect Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Connect Biopharmaceuticals Ltd filed Critical Suzhou Connect Biopharmaceuticals Ltd
Publication of MX2020011665A publication Critical patent/MX2020011665A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2020011665A 2018-05-04 2018-05-04 Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica. MX2020011665A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/085617 WO2019210511A1 (zh) 2018-05-04 2018-05-04 一种s1p1受体激动剂的加成盐及其晶型和药物组合物

Publications (1)

Publication Number Publication Date
MX2020011665A true MX2020011665A (es) 2021-01-20

Family

ID=68387039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011665A MX2020011665A (es) 2018-05-04 2018-05-04 Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica.

Country Status (13)

Country Link
US (3) US11512078B2 (enExample)
EP (2) EP4353719B1 (enExample)
JP (3) JP7275253B2 (enExample)
KR (2) KR102672632B1 (enExample)
AU (1) AU2018421487B2 (enExample)
CA (1) CA3099196A1 (enExample)
ES (1) ES2978392T3 (enExample)
IL (3) IL278464B2 (enExample)
MX (1) MX2020011665A (enExample)
NZ (1) NZ770323A (enExample)
SG (1) SG11202010969UA (enExample)
WO (1) WO2019210511A1 (enExample)
ZA (1) ZA202007347B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL278464B2 (en) * 2018-05-04 2024-10-01 Suzhou Connect Biopharmaceuticals Ltd Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
CA3201000A1 (en) * 2020-11-09 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
CN103450171B (zh) 2013-09-22 2015-07-08 苏州康乃德生物医药有限公司 一种免疫调节化合物、其用途和包含其的药物组合物
CN105315266B (zh) 2014-08-01 2019-10-01 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型
CN105348276B (zh) 2014-08-22 2020-05-26 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法
CN112778290B (zh) * 2017-01-11 2022-12-06 苏州康乃德生物医药有限公司 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
IL278464B2 (en) * 2018-05-04 2024-10-01 Suzhou Connect Biopharmaceuticals Ltd Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition

Also Published As

Publication number Publication date
IL278464B2 (en) 2024-10-01
IL312512B1 (en) 2025-11-01
US12202822B2 (en) 2025-01-21
JP2021532165A (ja) 2021-11-25
KR20240094023A (ko) 2024-06-24
SG11202010969UA (en) 2020-12-30
EP4353719B1 (en) 2025-12-24
EP3792258A1 (en) 2021-03-17
JP7651198B2 (ja) 2025-03-26
EP4353719A1 (en) 2024-04-17
KR102672632B1 (ko) 2024-06-07
JP2023062091A (ja) 2023-05-02
ZA202007347B (en) 2021-10-27
AU2018421487B2 (en) 2024-09-12
JP2025074350A (ja) 2025-05-13
US20210230152A1 (en) 2021-07-29
IL278464B1 (en) 2024-06-01
ES2978392T3 (es) 2024-09-11
EP3792258B1 (en) 2024-02-07
CA3099196A1 (en) 2019-11-07
US20250320200A1 (en) 2025-10-16
IL323665A (en) 2025-11-01
KR20210019999A (ko) 2021-02-23
IL278464A (enExample) 2021-03-01
JP7275253B2 (ja) 2023-05-17
IL312512B2 (en) 2026-03-01
BR112020022429A2 (pt) 2021-02-09
NZ770323A (en) 2025-12-19
IL312512A (en) 2024-07-01
US11512078B2 (en) 2022-11-29
WO2019210511A1 (zh) 2019-11-07
US20230050777A1 (en) 2023-02-16
AU2018421487A1 (en) 2020-12-17
EP3792258A4 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
BR112014012815A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
AR109300A2 (es) Formas cristalinas del ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BR112016015763B8 (pt) preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
JP2014139255A5 (enExample)
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
CO2019006652A2 (es) Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1
HK1203394A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
MX2020011665A (es) Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica.
CL2020000601A1 (es) Composición farmacéutica.
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
PH12019502767A1 (en) Oral pharmaceutical formulations of remogliflozin
RU2013147196A (ru) Агонист рецептора 5-нт4 в качестве прокинетического агента
MX378409B (es) Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.
CL2008003584A1 (es) Uso de la 10-[(3r)-1-azabiciclo]oct-3-ilmetil]-10-h-fenotiazina, o una de sus sales farmaceuticamente aceptables para la preparación de un medicamento util para prevenir o tratar la bronconeumopatia obstructiva.
JP2017530142A5 (enExample)